Full-Time

Computational Biologist

AI/ML

Updated on 9/4/2026

Verge Genomics

Verge Genomics

11-50 employees

Develops AI-powered drugs using human genomics

No salary listed

San Francisco, CA, USA

Remote

Master's, PhD

Category
Biology & Biotech (1)
Required Skills
LLM
Scikit-learn
Python
PyTorch
Machine Learning
OpenAI
RAG
Pandas
NumPy

Get referred to Verge Genomics

See people who can refer or advise you

Requirements
  • A PhD in computational biology, artificial intelligence or machine learning, applied statistics, or biophysics, or an MS with professional experience in relevant fields.
  • At least 5 years of experience in applied computational biology and integration of multi-omic datasets, including RNA sequencing, genotyping, and clinical data, with at least 2 years in a startup environment.
  • At least 2 years of experience in translational science, with understanding of target identification, biomarker discovery, and/or patient stratification.
  • Ability to implement, evaluate, and/or create computational methodologies using machine learning, statistics, and artificial intelligence for biological research and discovery.
  • Fluency in systems biology workflows, off-the-shelf biological databases, and computational biology tools.
  • A track record of bridging biological domain knowledge with computational approaches to solve scientific problems.
  • A track record of individual innovation, with published research or shipped work influencing pharmaceutical research and development decisions.
  • Experience conducting end-to-end RNA sequencing data analyses, including quality control, read quantification, normalization, and interpretation.
  • Excellent Python coding skills and experience with relevant machine learning and artificial intelligence libraries, including PyTorch, Hugging Face, scikit-learn, pandas, and NumPy.
  • Experience building and evaluating machine learning models on biological data, with understanding of feature selection and model interpretability.
  • Professional experience with artificial intelligence workflows, including natural language processing, retrieval-augmented generation, embeddings, vectorization of diverse data types, and large language models such as GPT.
  • Experience with model evaluation and experimental design in a scientific context, including appropriate benchmarks and controls.
Responsibilities
  • Work with Verge’s artificial intelligence partners to deliver a biology foundation model using Verge’s proprietary datasets.
  • Develop a novel approach enabling a product offering such as patient stratification or biomarker discovery.
  • Deliver at least two CONVERGE-powered insights projects to pharmaceutical or biotechnology companies.
  • Build an internal agentic artificial intelligence workflow supporting multimodal biomedical reasoning and orchestration.
  • Develop and evaluate computational methodologies integrating multi-omic datasets to create predictive models for translational biology.
  • Lead high-impact projects applying and adapting artificial intelligence models to translational challenges in disease biology, biomarker discovery, and target exploration.
  • Lead partnerships with artificial intelligence companies to co-develop foundation models for drug discovery.
  • Frame biological problems computationally and design biologically meaningful, interpretable, and experimentally testable solutions.
  • Design and implement evaluation methodologies for assessing artificial intelligence model capabilities relevant to biological research and applications.
  • Translate biological domain knowledge into machine learning objectives.
Desired Qualifications
  • A demonstrable portfolio, such as GitHub, research code, or shared notebooks.
  • Experience with transformer-based models such as scGPT, Geneformer, ESM, or ProtBERT.

Verge Genomics uses human genomics and AI to discover and develop drugs for diseases like ALS, Parkinson’s and Frontotemporal Dementia. It builds a large multi-omics database from human tissue and uses its CONVERGE platform to analyze the data and identify drug candidates, such as VRG50635, a PIKfyve inhibitor in ALS trials. The company relies on all-in-human data rather than traditional animal or cell models, aiming to map disease biology more directly and speed up drug discovery. Its goal is to bring effective therapies to patients faster by translating research into clinically available treatments.

Company Size

11-50

Company Stage

Series B

Total Funding

$134.1M

Headquarters

South San Francisco, California

Founded

2015

Get referred to Verge Genomics

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • June 9, 2026 Tenacia became Verge Labs' first platform-first CNS partnership.
  • May 2026 hires from Altos Labs, Calico, PostEra, and Flatiron strengthened commercialization.
  • Ferrer's 2024 ex-US license for VRG50635 still validates partner interest in Verge biology.

What critics are saying

  • December 2025 VRG50635 failure erased Verge's lead asset and clinical narrative.
  • May 2026 layoffs cut about 90% of staff, starving wet-lab execution.
  • If Tenacia revenues disappoint, Verge becomes a thin data vendor with no pipeline.

What makes Verge Genomics unique

  • Verge Labs trains CNS models on 12,000 brain samples from 6,500 patients.
  • May 2026 rebrand shifted Verge from molecule-maker to human-disease biology platform.
  • VRG50635 proved AI-discovered drugs can reach clinic, then revealed biological limits.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Excellent medical, dental, and vision coverage

401(k) plan with employer matching for contributions

Disability insurance, Life insurance, Dependant Care FSA and Healthcare FSA

Unlimited paid time off

Paid parental leave

Access to free onsite fitness center

Free snacks and lunch for employees who work onsite

WFH stipend for employees who work remotely

Growth & Insights and Company News

Headcount

6 month growth

-3%

1 year growth

-12%

2 year growth

-3%
AllSci
Jun 9th, 2026
Verge Labs to give AI platform boost to Tenacia's CNS programs.

Verge Labs to give AI platform boost to Tenacia's CNS programs. June 9, 2026 San Francisco-based Verge Labs has announced a platform collaboration with China-based Tenacia Biotechnology to apply its human tissue AI platform to select CNS programs in Tenacia's pipeline, marking the first deal under Verge's newly launched platform-first commercial model. The arrangement gives Tenacia access to Verge's multimodal brain dataset - described by the company as comprising more than 12,000 brain transcriptomes across 6,500 patients - to inform target selection and translational decisions before significant development resources are committed. Financial terms were not disclosed. Verge Labs, formerly known as Verge Genomics, rebranded and launched its platform-first model in May 2026, positioning itself as a provider of AI-driven biological intelligence to external drug developers rather than solely an internal pipeline company. Under the Tenacia arrangement, Verge will deploy its platform to characterize and prioritize targets across multiple CNS programs, grounding development decisions in direct human brain biology. The platform integrates bulk transcriptomics, single-cell profiling, proteomics, genomics, and matched clinical data from human tissue. Verge describes its approach as identifying dysregulated gene networks and the master regulator genes whose modulation could restore diseased networks toward a healthy expression state. The platform's prior clinical proof point is VRG50635, a PIKfyve inhibitor for ALS that completed a Phase I study in late 2025 - one of the few AI-discovered CNS candidates to reach human trials from any platform company. That program's ex-US rights were licensed to Ferrer for up to USD 122 million. Tenacia, founded in 2022 and backed by Bain Capital, has built its CNS pipeline primarily through in-licensing and AI-enabled discovery partnerships. The company previously expanded an AI-driven CNS collaboration with Insilico Medicine (HKEX: 3696) worth up to USD 94.75 million, adding a second generative AI-designed small-molecule program against an undisclosed neurological target. In March 2026, Tenacia also licensed RAP-219 from Rapport Therapeutics (Nasdaq: RAPP) in a deal worth up to USD 328 million, securing Greater China rights to a TARPγ8-selective AMPA receptor negative allosteric modulator in Phase II development for focal onset seizures and bipolar mania. The Verge partnership adds a distinct capability to that mix: rather than in-licensing molecules or contracting for generative chemistry, Tenacia is using human tissue data to validate and prioritize targets within its existing programs. Verge has stated that the Tenacia deal is the first of several CNS engagements now underway under its platform-first model, suggesting the company is actively scaling its commercial partnerships. This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/

PR Newswire
May 27th, 2026
Verge Labs launches frontier AI lab with 12,000-brain dataset to predict patient drug response

Verge Labs, formerly Verge Genomics, has relaunched as a frontier AI lab building foundation models of human disease biology. The San Francisco-based company is training models on over 12,000 human brain samples from 6,000 patients to predict individual patient responses to therapy. The company's platform uses proprietary brain tissue data to create "virtual biopsies" that simulate a patient's brain biology from blood draws. Targets identified by the platform have achieved 83% validation against experimental confirmation, and its first AI-discovered drug completed Phase 1b trials in late 2025. Verge Labs announced four senior hires from Altos Labs, Calico, PostEra and Flatiron Health across AI, business and computational biology. Founded in 2015, the company is partnering with select drug developers on CNS programmes.

Labiotech
Jan 22nd, 2025
Curing Als? Thirteen Companies Developing New Treatments In 2025

Newsletter Signup - Under Article / In Page"*" indicates required fields Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord, leading to the loss of muscle control. As motor neurons deteriorate, patients experience muscle weakness, paralysis, and eventually respiratory failure. The exact cause of ALS remains unknown, and currently, there is no cure.The treatment options for ALS are limited, focusing primarily on slowing disease progression and managing symptoms. The treatment landscape for ALS has only seen modest advancements over the past few decades.Approved in 1995, Riluzole modestly prolongs survival in ALS patients by reducing the release of glutamate, a neurotransmitter that can be toxic to motor neurons at high levels. An important advancement in the field has to be tofersen’s approval by the U.S. Food and Drug Administration (FDA) in 2023 which was a significant step forward in personalized treatment for ALS.The lack of treatment options finds its explanation in a particularly challenging disease area

The Tokenist
Nov 20th, 2024
LLY Stock Rebounds Amid AI-Driven ALS Research Breakthroughs

Verge Genomics and Eli Lilly (NYSE: LLY) have announced significant progress in their joint efforts to develop novel treatments for amyotrophic lateral sclerosis (ALS), a debilitating neurodegenerative disease.

Labiotech
Jul 11th, 2024
Five Bioinformatics Companies Making Waves In The Biopharma Industry In 2024

Bioinformatics is a field of science that integrates computer technology to analyze biological data, particularly DNA and protein sequences, to advance therapies and boost healthcare research. In this article, we take a look at five companies at the top of their bioinformatics game in 2024.SynthaceBritish-American life science company Synthace’s DNA Assembly platform allows people to import assembly design files at the start of the workflow, after which, it helps create the plasmids – circular DNA molecules found in microbes – that are required for projects.Once customers specify what kind of plasmid they want designed, Synthace’s platform calculates the liquid movements, concentrations, and dilutions needed throughout the entire process. The company helps estimate reagent volumes as well as automation instructions for customers to be able to run experiments without having to use spreadsheets or any kind of programming. With a focus on molecular biology, the bioinformatics company aids scientists in planning and automating processes like DNA assembly for their research and development (RD) projects.Synthace has previously worked with tech giants like Microsoft to design manufacturing processes for lentiviral vectors to be able to program cells to discover new medicines. It has also collaborated with global biopharma Ipsen to develop medicines to treat rare diseases and pain relief.  The company has also been known to use OpenAI’s ChatGPT to design complex experiments.Last year, Synthace was among 50 companies like Google, mental healthcare company Headspace, and food company Beyond Meat, to win the international Impact Fifty award recognizing the most impactful companies to work for.Verge GenomicsImmersed in the drug discovery space, Verge Genomics leverages artificial intelligence (AI) to discover and develop drugs. Its CONVERGE discovery platform is a closed-loop machine learning system that combines genomics and computational tools to scout for drug targets and predict how well investigational medicines could perform in the clinic.This way, it looks to develop drugs at a faster rate. In its pipeline, Verge has an amyotrophic lateral sclerosis (ALS) drug undergoing proof-of-concept studies. ALS is a fatal motor neuron disease that affects the nerve cells in the spinal cord and brain